MyoKardia Shareholders Are Getting a Really Sweet Payday

Health and Healthcare

Published: October 5, 2020 10:07 am

MyoKardia Inc. (NASDAQ: MYOK) shares hit an all-time high early on Monday after it was announced that Bristol-Myers Squibb Co. (NYSE: BMY) would be acquiring the company. Needless to say, shareholders are getting a solid payout for their shares in this all-cash deal.

Under the terms of the deal, Bristol-Myers Squibb will acquire all outstanding shares of MyoKardia for $225 per share, for a total consideration of $13.1 billion. This price tag offers premiums of 101% and 165% from the stock’s 50-day and 200-day moving averages of $111.88 and $84.80, respectively.

Keep in mind that MyoKardia only came pubic in the fall of 2015 and since then shares have risen over 2,200% (including Monday’s move).

MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases.

Through the transaction, Bristol-Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy (HCM), a chronic heart disease with high morbidity and patient impact. A New Drug Application (NDA) for mavacamten for the treatment of symptomatic obstructive HCM (based on data from the EXPLORER-HCM study) is expected to be submitted to the U.S. Food and Drug Administration in the first quarter of 2021.

Bristol-Myers Squibb expects to explore the full potential of mavacamten in additional indications, including non-obstructive HCM, as well as develop MyoKardia’s promising pipeline of novel compounds, including two clinical-stage therapeutics: danicamtiv (formerly MYK-491) and MYK-224.

The deal was approved unanimously by both boards of directors and is anticipated to close during the fourth quarter of 2020.

Bristol-Myers Squibb stock traded down 1.1% Monday morning to $58.00, in a 52-week range of $45.76 to $68.34. The consensus price target is $73.62.

MyoKardia stock traded up 58% to $220.72, above the prior 52-week range of $42.65 to $140.93. The consensus price target is $137.45.

ALSO READ: Top Analyst Very Positive on Leading Medical Technology Health Care Stocks for 2021

The Average American Is Losing Momentum On Their Savings Every Day (Sponsor)

If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4%¹ today. Checking accounts are even worse.

But there is good news. To win qualified customers, some accounts are paying more than 7x the national average. That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn a $200 bonus and up to 7X the national average with qualifying deposits. Terms apply. Member, FDIC.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

¹https://www.fdic.gov/national-rates-and-rate-caps